5-MTHF prenatal trial: what the Ritual-funded RCT actually showed

Folic acid fortification was one of the great public-health bets the United States made in the late twentieth century, and like most bets that worked, the dose-versus-mechanism trade-offs got a thinner reading once the headline outcome looked good. The 1998 FDA mandate to add folic acid to enriched cereal grains cut neural tube defect rates by about a third, with comparable gains in countries that copied the move. That part is settled. Less discussed is that the policy ran a population-scale experiment with a synthetic form of folate that human metabolism never quite evolved to handle in steady, large daily doses. The active form circulating in human blood is 5-methyltetrahydrofolate, abbreviated 5-MTHF. To get there, folic acid first has to be reduced and then methylated by the liver, and the conversion saturates earlier than most people would guess.

That bottleneck has driven a quiet reformulation in the prenatal aisle. A randomized trial published last week in Frontiers in Nutrition, run out of City University of New York and funded by the supplement brand Ritual, is the cleanest attempt yet to ask whether replacing folic acid with 5-MTHF in pregnancy actually does what the marketing implies. Short answer for the second and third trimesters: yes, with caveats. Long answer: read the funding line, the sample size, and the unresolved UMFA debate carefully before treating this as a verdict on prenatal choice.

The conversion bottleneck

Most dietary folate enters the body partially reduced, through leafy greens, legumes, and the natural folates in some animal foods. The gut wall and liver finish the conversion to 5-MTHF, which is what red blood cells and tissues actually use. Synthetic folic acid is fully oxidized. It has to run through dihydrofolate reductase first, then through several methylation steps, before it reaches the active form. The first step is the bottleneck. Dihydrofolate reductase saturates at modest folic acid intakes, somewhere around 200 micrograms per day in many adults, and once it does, the unconverted folic acid spills into circulation as UMFA.

Genetics adds another layer. The MTHFR enzyme converts 5,10-methylenetetrahydrofolate to 5-MTHF further downstream. The C677T polymorphism in MTHFR reduces enzyme activity by about 70 percent in homozygotes and around 35 percent in heterozygotes. Variant frequencies vary by ancestry, but somewhere between a quarter and 40 percent of the global population carries at least one copy. For these people, the gap between folic acid intake and active 5-MTHF in tissues is wider than for unaffected individuals.

This is the biochemistry that has driven the supplement industry’s pivot toward 5-MTHF, sometimes branded L-methylfolate or sold under the trade name Quatrefolic. The premise has been straightforward. Hand the body the active form and it skips the bottleneck. Until recently the trial evidence specifically in pregnancy was thin.

The CUNY trial

Xinyin Jiang, professor of health and nutrition sciences at CUNY, ran a 24-week randomized double-blind trial in 62 pregnant women starting in the second trimester. One arm got a prenatal multivitamin formulated with 6S-5-MTHF, which corresponds to the Ritual Essential Prenatal product. The other arm got a comparator prenatal built around folic acid. The folic acid arm received roughly 30 percent more total folate by mass, which is a wrinkle worth flagging.

The team measured folate status across maternal blood, cord blood, and placental tissue, and tracked UMFA in circulation and in placental tissue.

Two findings carry the paper.

Folate status held. Maternal, cord, and placental folate levels were comparable between the two arms even though the folic acid arm got more total folate by mass. The methylated form maintained the same folate status with less raw input.

UMFA dropped. Detectable unmetabolized folic acid in maternal blood was found in 7 percent of the 5-MTHF arm versus 31 percent of the folic acid arm. Placental UMFA followed the same pattern.

“5-MTHF can maintain folate status just as effectively as folic acid, but with significantly less unmetabolized folic acid circulating in the body,” Jiang said in the press release. The paper itself uses tighter language, reporting that “supplementation with a 5-MTHF-containing MVI significantly reduced UMFA concentrations in maternal blood and placenta.”

Why UMFA matters, or might

The case against UMFA is built on observational signals, not randomized outcome data. Studies in older adults have linked persistent UMFA in circulation to altered natural killer cell function. Other work has raised the possibility that UMFA can mask a B12 deficiency by correcting macrocytic anemia without addressing the underlying neurological consequences. Whether any of this matters in pregnancy is genuinely unknown. The right summary of the current evidence is “uncertain, with biologically plausible reasons to want less of it” rather than “proven harmful.”

The Jiang trial does not resolve that uncertainty. What it offers is a way to reduce UMFA exposure during the second and third trimesters without sacrificing folate status. That is a useful intermediate finding even before any long-term outcome data exists, and it is honest enough about what it is.

Three caveats worth holding

The trial was funded by Ritual. The active arm was Ritual’s flagship prenatal product. Industry funding does not invalidate a finding, but it does set a higher bar for independent replication. The university lead and peer-reviewed venue are appropriate signals that the data are real, but a non-industry replication would strengthen the case considerably. Anyone reading the press release without reading the funding line is missing context.

The sample size, 62 evaluable participants, is modest for a pregnancy nutrition outcome. The trial measured surrogate markers, folate levels and UMFA, and not pregnancy outcomes like neural tube defect rates or birth weight. The current evidence base for preventing neural tube defects rests on folic acid trials from the 1990s using folic acid, not 5-MTHF. The strongest periconceptional and first-trimester recommendation, both from the FDA and from the American College of Obstetricians and Gynecologists, remains 400 to 800 micrograms of folic acid daily before and during early pregnancy.

The trial deliberately excluded the first trimester. That is the right window for a UMFA-in-steady-state question and the wrong window for a “5-MTHF should replace folic acid throughout pregnancy” claim. Coverage that elides this distinction is not reading the study carefully.

A 2025 ScienceDirect feasibility trial out of Australia, randomizing 22 reproductive dyads to 5-MTHF versus folic acid before pregnancy, suggested the design was feasible but was underpowered for outcomes. The CUNY study is a meaningful step up in scale. It is not a definitive answer.

What this changes for prenatal choice

A patient in the periconceptional window or the first trimester should not change anything based on this trial. Folic acid still has the strongest neural tube defect evidence, and that window is when the evidence matters most. The CUNY study did not test it, and the existing recommendation should not be relaxed on the strength of a different trimester.

A patient in the second or third trimester who is already on a 5-MTHF-based prenatal can read the new data as reassurance. Folate status is being maintained. UMFA exposure is meaningfully lower. There is no obvious reason to switch back to folic acid for the rest of the pregnancy.

A patient with a known MTHFR variant whose obstetrician has already steered them toward methylated folate now has more trial-grade evidence to lean on for the second and third trimesters specifically. The trial does not yet support the larger claim that 5-MTHF improves fetal outcomes, only that it maintains folate status with less UMFA.

The product caveat is unavoidable. The active arm of this trial was the Ritual Essential Prenatal formulation, which means the result is most directly generalizable to that product and to other prenatal multivitamins built around 6S-5-MTHF at comparable doses. Generic claims that any “methylated folate” prenatal will behave the same way, without dose verification, run further than the trial supports.

Consult your doctor or obstetrician before starting any supplement during pregnancy. The form, dose, and timing relative to conception all matter, and the right answer depends on individual genetics, dietary intake, and clinical history rather than on any single trial result.